摘要
目的 研究新辅助化疗 (MVP)是否影响非小细胞肺癌患者围手术期的安全性。方法 所有患者化疗方案均为MVP ,即丝裂霉素 (MMC) +长春碱胺 (VDS) +顺铂 (DDP)。将接受 2周期术前新辅助化疗、根治性手术和 2次术后化疗的患者与接受同样手术和 4次术后化疗的患者进行比较。结果 在 10 7例符合要求的病例中 ,新辅助化疗组有 66例 ,对照组有 41例 ,两组在性别、年龄、肿瘤分期、病理类型上均无统计学差异。新辅助化疗组患者的手术时间 (P =0 .2 62 )、术中失血量 (P =0 .70 4)、术中输血量 (P =0 .811)、输血总量 (P =0 .0 74)比对照组患者略高 ,术后总引流量 (P =0 .0 61)稍低 ,但其差异均无统计学意义。两组术后死亡率 (P =0 .674)和并发症 :心律失常 (P =0 .60 8)、支气管胸膜瘘 (P =0 .3 78)、肺炎 (P =0 .62 2 )、呼吸衰竭 (P=0 .2 85 )的比较亦均无统计学意义。结论 新辅助化疗对非小细胞肺癌患者围手术期的安全性无显著影响。
Objective To investigate whether neoadjuvant chemotherapy (MVP) could influence the safety of perioperative patients with non-small cell lung cancer (NSCLC). Methods The regimen of chemotherapy was MVP (mitomycin+vindesine+cisplatin) for all patients. The patients undergoing 2 cycles of neoadjuvant chemotherapy, radical resection and 2 cycles of postoperative chemotherapy were compared with those undergoing similar resections and 4 cycles of similar postoperative chemotherapy. Results Of the 107 eligible patients, 66 patients were in the neoadjuvant-chemotherapy group and 41 in control group. There was no statistical difference between these two groups in the distributions of gender, age, tumor staging and pathology. The neoadjuvant-chemotherapy group had longer operative duration (P=0.262), more operative blood loss (P=0.704), more amount of operative transfusion (P=0.811) and total amount of perioperative transfusion (P=0.074), and less amount of post-operative drainage (P=0.061) than those of the control group, but no statistical difference was found among them. No statistical difference was detected between two groups in the mortality (P=0.674) and the morbidity such as arrhythmia (P=0.608), bronchial parietal fistula (P= 0.378 ), pneumonia (P=0.622) and respiratory failure (P=0.285). Conclusion Neoadjuvant chemotherapy does not exert significant influence on the safety of perioperative patients with NSCLC.
出处
《中国肺癌杂志》
CAS
2003年第6期488-491,共4页
Chinese Journal of Lung Cancer
基金
上海市医学领先专业重点学科建设研究课题 (No.94 Ⅲ 0 1 1 )~~
关键词
化疗
围手术期
非小细胞肺癌
MVP
并发症
Neoadjuvant chemotherapy Non-small cell lung cancer MVP Perioperation
